← Leaderboards
Scott K Heysell
University Of Virginia
$9,245,019
Attributed
$14,204,081
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,204,081 · 9
By mechanism
U01$7,017,735 · 3
R01$5,004,674 · 2
D43$1,145,152 · 1
K23$649,350 · 1
R34$241,000 · 1
K24$146,170 · 1
Top collaborators
- Christopher Charles Moore8 shared
- Eric R Houpt6 shared
- Stellah George Mpagama5 shared
- Leonid Kagan2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Eric R Houpt$18,307,652
- Christopher Charles Moore$2,587,971
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisCessation Of LifeTanzaniaTuberculosis TreatmentPharmaceutical PreparationsAntitubercular AgentsDoseRegimenRifampinIsoniazidDrug KineticsTuberculosis DrugsAdultCommunicable DiseasesDesignSerumAreaInfectionSiteVirginiaMycobacterium TuberculosisMortalityTreatment FailureWorld Health Organization
Grant awards (35)
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$728,725
R01 · FY2025 · AI · contact PI
STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial$361,931
U01 · FY2025 · AI · contact PI
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania$248,288
D43 · FY2025 · TW · contact PI
STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial$151,200
U01 · FY2025 · AI · contact PI
STeroids and enhanced Antibiotics for the treatment of patients in Africa with Refractory Sepsis: STARS trial$151,200
U01 · FY2025 · AI · contact PI
A global Infectious diseases framework to grow interdisciplinary research$146,170
K24 · FY2025 · AI · contact PI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$785,512
R01 · FY2024 · AI · contact PI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$659,026
U01 · FY2024 · AI · contact PI
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania$248,288
D43 · FY2024 · TW · contact PI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$669,513
U01 · FY2023 · AI · contact PI
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania$248,288
D43 · FY2023 · TW · contact PI
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania$150,000
D43 · FY2023 · TW · contact PI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$669,133
R01 · FY2022 · AI · contact PI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$657,831
U01 · FY2022 · AI · contact PI
Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania$250,288
D43 · FY2022 · TW · contact PI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$767,879
R01 · FY2021 · AI · contact PI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$662,780
U01 · FY2021 · AI · contact PI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$202,634
R01 · FY2021 · AI · contact PI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$792,488
R01 · FY2020 · AI · contact PI
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa$682,830
U01 · FY2020 · AI · contact PI
Diagnostics and Pharmacotherapy for Severe Forms of TB$648,811
U01 · FY2019 · AI · contact PI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults$458,304
R01 · FY2019 · AI · contact PI
Individualized approaches to the HIV/TB epidemic among polysubstance users in Irkutsk$220,000
R01 · FY2019 · DA · contact PI
Diagnostics and Pharmacotherapy for Severe Forms of TB$656,184
U01 · FY2018 · AI · contact PI
Individualized approaches to the HIV/TB epidemic among polysubstance users in Irkutsk$180,000
R01 · FY2018 · DA · contact PI
Diagnostics and Pharmacotherapy for Severe Forms of TB$657,815
U01 · FY2017 · AI · contact PI
Individualized approaches to the HIV/TB epidemic among polysubstance users in Irkutsk$199,999
R01 · FY2017 · DA · contact PI
Diagnostics and Pharmacotherapy for Severe Forms of TB$673,914
U01 · FY2016 · AI · contact PI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility$129,870
K23 · FY2016 · AI · contact PI
Diagnostics and Pharmacotherapy for Severe Forms of TB$384,700
U01 · FY2015 · AI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility$129,870
K23 · FY2015 · AI · contact PI
Reduced Injectable, Short-course for (E)Xpert MDR-TB [RISE trial]$241,000
R34 · FY2014 · AI · contact PI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility$129,870
K23 · FY2014 · AI · contact PI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility$129,870
K23 · FY2013 · AI · contact PI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility$129,870
K23 · FY2012 · AI · contact PI